Unlocking the Promise of Genome Editing to DeliverĀ Life-Changing Medicines

Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.

Read More


Editas News

March 2, 2015
Editas Medicine Reports Data Demonstrating the Potential of CRISPR/Cas9 to Enable Gene Repair Through a New Mechanism Read More

Publications & Abstracts

March 2, 2015
Gene targeting of the HBB locus by Crispr/Cas9 to investigate repair pathway choice in response to different types of DNA lesions  Read More

January 12, 2015
Staphyloccocus aureus Cas9: An alternative Cas9 for genome editing applications. Read More

December 10, 2014
NCBI: Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex.     Read More

October 30, 2014
Nature Biotechnology: Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo.   Read More

October 19, 2014
Nature Biotechnology: In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9.     Read More

October 9, 2014
Cell: CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling.        Read More

September 28, 2014
Nature: Programmable RNA recognition and cleavage by CRISPR/Cas9.   Read More

August 11, 2014
Nature Methods: Improved vectors and genome-wide libraries for CRISPR screening.     Read More

July 1, 2014
Bioinformatics: Genome editing assessment using CRISPR Genome Analyzer (CRISPR-GA).   Read More